{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T03:39:15Z","timestamp":1784000355320,"version":"3.55.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.phrs.2022.106565","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T11:22:51Z","timestamp":1668856971000},"page":"106565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Upgrade of chrysomycin A as a novel topoisomerase II inhibitor to curb KRAS-mutant lung adenocarcinoma progression"],"prefix":"10.1016","volume":"187","author":[{"given":"Junmin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine Lai-Han","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Jun","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.phrs.2022.106565_bib1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2022.106565_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104551","article-title":"Topoisomerase inhibitors: Pharmacology and emerging nanoscale delivery systems","volume":"151","author":"Dehshahri","year":"2020","journal-title":"Pharmacol. Res"},{"issue":"6","key":"10.1016\/j.phrs.2022.106565_bib3","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.apsb.2018.07.008","article-title":"Recent developments in topoisomerase-targeted cancer chemotherapy","volume":"8","author":"Hevener","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.phrs.2022.106565_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3389\/fmolb.2019.00141","article-title":"Strand breaks and chromosomal translocations induced by DNA topoisomerase II","volume":"6","author":"Gomez-Herreros","year":"2019","journal-title":"Front Mol. Biosci."},{"issue":"7511","key":"10.1016\/j.phrs.2022.106565_bib5","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nature13442","article-title":"Topoisomerase II mediates meiotic crossover interference","volume":"511","author":"Zhang","year":"2014","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.phrs.2022.106565_bib6","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1021\/cr200325f","article-title":"Contemporary challenges in the design of topoisomerase II inhibitors for cancer chemotherapy","volume":"112","author":"Bailly","year":"2012","journal-title":"Chem. Rev."},{"issue":"5","key":"10.1016\/j.phrs.2022.106565_bib7","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrc2607","article-title":"Targeting DNA topoisomerase II in cancer chemotherapy","volume":"9","author":"Nitiss","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.phrs.2022.106565_bib8","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1172\/JCI127471","article-title":"cGAS\/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity","volume":"129","author":"Wang","year":"2019","journal-title":"J. Clin. Invest"},{"issue":"12","key":"10.1016\/j.phrs.2022.106565_bib9","doi-asserted-by":"crossref","first-page":"6654","DOI":"10.1093\/nar\/gkaa483","article-title":"Topoisomerase II contributes to DNA secondary structure-mediated double-stranded breaks","volume":"48","author":"Szlachta","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"20","key":"10.1016\/j.phrs.2022.106565_bib10","doi-asserted-by":"crossref","first-page":"8947","DOI":"10.1021\/acs.jmedchem.7b01202","article-title":"Discovery of novel topoisomerase II inhibitors by medicinal chemistry approaches","volume":"61","author":"Hu","year":"2018","journal-title":"J. Med Chem."},{"issue":"8","key":"10.1016\/j.phrs.2022.106565_bib11","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1073\/pnas.1921649117","article-title":"The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning","volume":"117","author":"Bruno","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"11","key":"10.1016\/j.phrs.2022.106565_bib12","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.3390\/cells10113138","article-title":"Topoisomerase II inhibitor with dose-affected anticancer mechanisms and less cardiotoxicity","volume":"10","author":"Li","year":"2021","journal-title":"Cells"},{"issue":"18","key":"10.1016\/j.phrs.2022.106565_bib13","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1016\/j.bmc.2018.09.021","article-title":"A new phenolic series of indenopyridinone as topoisomerase inhibitors: Design, synthesis, and structure-activity relationships","volume":"26","author":"Shrestha","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2022.106565_bib14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/14756366.2021.2007905","article-title":"Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies","volume":"37","author":"Khalifa","year":"2022","journal-title":"J. Enzym. Inhib. Med Chem."},{"key":"10.1016\/j.phrs.2022.106565_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104049","article-title":"Discovery of new ATP-competitive inhibitors of human DNA topoisomerase IIalpha through screening of bacterial topoisomerase inhibitors","volume":"102","author":"Skok","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phrs.2022.106565_bib16","first-page":"7","article-title":"Cancer Statistics, 2021","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.phrs.2022.106565_bib17","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/jamaoncol.2016.4280","article-title":"Comparison of concurrent use of thoracic radiation with either carboplatin-paclitaxel or cisplatin-etoposide for patients with stage III non-small-cell lung cancer: a systematic review","volume":"3","author":"Steuer","year":"2017","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106565_bib18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.phrs.2022.106565_bib19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"7546","key":"10.1016\/j.phrs.2022.106565_bib20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature14122","article-title":"EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors","volume":"520","author":"Fillmore","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2022.106565_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108050","article-title":"Resistance looms for KRAS G12C inhibitors and rational tackling strategies","volume":"229","author":"Zhang","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2022.106565_bib22","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pharmthera.2018.06.010","article-title":"Novel therapeutic strategy for cancer and autoimmune conditions: Modulating cell metabolism and redox capacity","volume":"191","author":"Fan","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2022.106565_bib23","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/gutjnl-2020-321031","article-title":"Ginseng polysaccharides alter the gut microbiota and kynurenine\/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1\/programmed cell death ligand 1 (anti-PD-1\/PD-L1) immunotherapy","volume":"71","author":"Huang","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2022.106565_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105656","article-title":"Plumbagin suppresses non-small cell lung cancer progression through downregulating ARF1 and by elevating CD8(+) T cells","volume":"169","author":"Jiang","year":"2021","journal-title":"Pharmacol. Res"},{"key":"10.1016\/j.phrs.2022.106565_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105129","article-title":"Dolutegravir derivative inhibits proliferation and induces apoptosis of non-small cell lung cancer cells via calcium signaling pathway","volume":"161","author":"Wang","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"5","key":"10.1016\/j.phrs.2022.106565_bib26","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/ijc.32222","article-title":"Identification of a new inhibitor of KRAS-PDEdelta interaction targeting KRAS mutant nonsmall cell lung cancer","volume":"145","author":"Leung","year":"2019","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.phrs.2022.106565_bib27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.phrs.2019.03.011","article-title":"Cordycepin inhibits drug-resistance non-small cell lung cancer progression by activating AMPK signaling pathway","volume":"144","author":"Wei","year":"2019","journal-title":"Pharm. Res"},{"issue":"3","key":"10.1016\/j.phrs.2022.106565_bib28","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"T. International natural product sciences, C.T. Supuran, natural products in drug discovery: advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.phrs.2022.106565_bib29","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/med.21348","article-title":"Toward a cancer drug of fungal origin","volume":"35","author":"Kornienko","year":"2015","journal-title":"Med. Res Rev."},{"key":"10.1016\/j.phrs.2022.106565_bib30","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-biochem-062917-011942","article-title":"Ribosome-targeting antibiotics: modes of action, mechanisms of resistance, and implications for drug design","volume":"87","author":"Lin","year":"2018","journal-title":"Annu Rev. Biochem"},{"issue":"Pt 2","key":"10.1016\/j.phrs.2022.106565_bib31","first-page":"998","article-title":"Bacteria as a treasure house of secondary metabolites with anticancer potential","volume":"86","author":"Mohan","year":"2021","journal-title":"Semin Cancer Biol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106565_bib32","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1128\/jb.69.3.280-283.1955","article-title":"Chrysomycin: a new antibiotic substance for bacterial viruses","volume":"69","author":"Strelitz","year":"1955","journal-title":"J. Bacteriol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106565_bib33","first-page":"131","article-title":"Chrysomycin in suppurative surgical and gynecological disorders","volume":"6","author":"Sava","year":"1954","journal-title":"Bul. Stiint. Sect. Stiint. Med. Acad. Repub. Pop. Rom."},{"issue":"9","key":"10.1016\/j.phrs.2022.106565_bib34","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.7164\/antibiotics.42.1446","article-title":"Antitumor activity of chrysomycins M and V","volume":"42","author":"Matson","year":"1989","journal-title":"J. Antibiot."},{"issue":"9","key":"10.1016\/j.phrs.2022.106565_bib35","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.7164\/antibiotics.35.1194","article-title":"The chemistry of the antibiotics chrysomycin A and B. Antitumor activity of chrysomycin A","volume":"35","author":"Weiss","year":"1982","journal-title":"J. Antibiot."},{"issue":"7","key":"10.1016\/j.phrs.2022.106565_bib36","first-page":"507","article-title":"Separation and characteristics of the components of the antibiotic virenomycin","volume":"27","author":"Kudinova","year":"1982","journal-title":"Antibiotiki"},{"issue":"12","key":"10.1016\/j.phrs.2022.106565_bib37","first-page":"884","article-title":"Structure of the antibiotic virenomycin","volume":"29","author":"Brazhnikova","year":"1984","journal-title":"Antibiotiki"},{"issue":"43","key":"10.1016\/j.phrs.2022.106565_bib38","doi-asserted-by":"crossref","first-page":"21046","DOI":"10.1039\/c3ra42884b","article-title":"Chrysomycins A\u2013C, antileukemic naphthocoumarins from Streptomyces sporoverrucosus","volume":"3","author":"Jain","year":"2013","journal-title":"RSC Adv."},{"issue":"58","key":"10.1016\/j.phrs.2022.106565_bib39","doi-asserted-by":"crossref","first-page":"36335","DOI":"10.1039\/C7RA05576E","article-title":"Anti-microbial activity of chrysomycin A produced by Streptomyces sp. against Mycobacterium tuberculosis","volume":"7","author":"Muralikrishnan","year":"2017","journal-title":"RSC Adv."},{"issue":"6","key":"10.1016\/j.phrs.2022.106565_bib40","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1021\/acscentsci.0c00122","article-title":"Chrysomycin A derivatives for the treatment of multi-drug-resistant tuberculosis","volume":"6","author":"Wu","year":"2020","journal-title":"ACS Cent. Sci."},{"issue":"08","key":"10.1016\/j.phrs.2022.106565_bib41","doi-asserted-by":"crossref","first-page":"0986","DOI":"10.1055\/s-0040-1706817","article-title":"Chrysomycin A and derivatives against multi-drug-resistant tuberculosis","volume":"16","author":"Trauner","year":"2020","journal-title":"Synfacts"},{"issue":"4","key":"10.1016\/j.phrs.2022.106565_bib42","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41429-022-00503-z","article-title":"Chrysomycin A inhibits the topoisomerase I of Mycobacterium tuberculosis","volume":"75","author":"Muralikrishnan","year":"2022","journal-title":"J. Antibiot."},{"issue":"13","key":"10.1016\/j.phrs.2022.106565_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22136799","article-title":"Chrysomycin A attenuates neuroinflammation by down-regulating NLRP3\/cleaved caspase-1 signaling pathway in LPS-stimulated mice and BV2 cells","volume":"22","author":"Liu","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2022.106565_bib44","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/cjoc.202000509","article-title":"Function-oriented natural product synthesis","volume":"39","author":"Chen","year":"2021","journal-title":"Chin. J. Chem."},{"issue":"11","key":"10.1016\/j.phrs.2022.106565_bib45","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1021\/acs.accounts.0c00531","article-title":"New strategies in the efficient total syntheses of polycyclic natural products","volume":"53","author":"Liu","year":"2020","journal-title":"Acc. Chem. Res"},{"issue":"10","key":"10.1016\/j.phrs.2022.106565_bib46","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1080\/10826068.2021.1885046","article-title":"Optimization of fermentation conditions and medium compositions for the production of chrysomycin a by a marine-derived strain Streptomyces sp. 891","volume":"51","author":"Ni","year":"2021","journal-title":"Prep. Biochem. Biotechnol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106565_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/md20050287","article-title":"Comprehensive genomic analysis of marine strain Streptomyces sp. 891, an excellent producer of chrysomycin A with therapeutic potential","volume":"20","author":"Hu","year":"2022","journal-title":"Mar. Drugs"},{"issue":"7","key":"10.1016\/j.phrs.2022.106565_bib48","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med Chem."},{"issue":"21","key":"10.1016\/j.phrs.2022.106565_bib49","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1021\/jm051256o","article-title":"Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes","volume":"49","author":"Friesner","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2022.106565_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104884","article-title":"Synthesis and structure-activity relationships of hydroxylated and halogenated 2,4-diaryl benzofuro[3,2-b]pyridin-7-ols as selective topoisomerase IIalpha inhibitors","volume":"111","author":"Thapa Magar","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"18","key":"10.1016\/j.phrs.2022.106565_bib51","first-page":"4909","article-title":"Inhibition of intracellular topoisomerase-Ii by antitumor Bis(2,6-Dioxopiperazine) derivatives - mode of cell-growth inhibition distinct from that of cleavable complex-forming type inhibitors","volume":"51","author":"Ishida","year":"1991","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2022.106565_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108977","article-title":"Topoisomerase IIalpha represses transcription by enforcing promoter-proximal pausing","volume":"35","author":"Herrero-Ruiz","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.phrs.2022.106565_bib53","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.phymed.2018.06.025","article-title":"Phytochemical naphtho[1,2-b] furan-4,5dione induced topoisomerase II-mediated DNA damage response in human non-small-cell lung cancer","volume":"54","author":"Chien","year":"2019","journal-title":"Phytomedicine"},{"issue":"2","key":"10.1016\/j.phrs.2022.106565_bib54","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41419-017-0065-9","article-title":"Inhibition of KRAS-dependent lung cancer cell growth by deltarasin: blockage of autophagy increases its cytotoxicity","volume":"9","author":"Leung","year":"2018","journal-title":"Cell Death Dis."},{"issue":"21","key":"10.1016\/j.phrs.2022.106565_bib55","doi-asserted-by":"crossref","first-page":"16132","DOI":"10.1021\/acs.jmedchem.1c01441","article-title":"Structural modification of aminophenylarsenoxides generates candidates for leukemia treatment via thioredoxin reductase inhibition","volume":"64","author":"Song","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2022.106565_bib56","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1080\/14756366.2021.1899169","article-title":"Onopordopicrin from the new genus Shangwua as a novel thioredoxin reductase inhibitor to induce oxidative stress-mediated tumor cell apoptosis","volume":"36","author":"Zhang","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"11","key":"10.1016\/j.phrs.2022.106565_bib57","first-page":"1362","article-title":"Antibiotics from marine bacteria","volume":"85","author":"Stonik","year":"2020","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2022.106565_bib58","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3389\/fphar.2017.00823","article-title":"Identification of a new potent inhibitor targeting KRAS in non-small cell lung cancer cells","volume":"8","author":"Xie","year":"2017","journal-title":"Front Pharm."},{"issue":"3\u20134","key":"10.1016\/j.phrs.2022.106565_bib59","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0009-2797(88)90062-2","article-title":"The effects of gilvocarcin V and ultraviolet radiation on pBR322 DNA and lymphocytes","volume":"67","author":"Gasparro","year":"1988","journal-title":"Chem. Biol. Inter."},{"issue":"10","key":"10.1016\/j.phrs.2022.106565_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101169","article-title":"Etoposide, an anticancer drug involved in therapy-related secondary leukemia: Enzymes at play","volume":"14","author":"Zhang","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.phrs.2022.106565_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104913","article-title":"Discovery of 5-(or 6)-benzoxazoles and oxazolo[4,5-b]pyridines as novel candidate antitumor agents targeting hTopo IIalpha","volume":"112","author":"Karatas","year":"2021","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2022.106565_bib62","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/14756366.2022.2140420","article-title":"Identification of the first-in-class dual inhibitors of human DNA topoisomerase IIalpha and indoleamine-2,3-dioxygenase 1 (IDO 1) with strong anticancer properties","volume":"38","author":"Kapron","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"17","key":"10.1016\/j.phrs.2022.106565_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27175561","article-title":"Discovery of quinacrine as a potent topo II and Hsp90 dual-target inhibitor, repurposing for cancer therapy","volume":"27","author":"Pan","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2022.106565_bib64","series-title":"Helicases from All Domains of Life","first-page":"235","article-title":"Assaying the activity of helicases","author":"Mojumdar","year":"2019"},{"issue":"10","key":"10.1016\/j.phrs.2022.106565_bib65","doi-asserted-by":"crossref","DOI":"10.1002\/cpz1.250","article-title":"Topoisomerase assays","volume":"1","author":"Nitiss","year":"2021","journal-title":"Curr. Protoc."},{"issue":"1","key":"10.1016\/j.phrs.2022.106565_bib66","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/med.21734","article-title":"Small molecules regulating reactive oxygen species homeostasis for cancer therapy","volume":"41","author":"Zhang","year":"2021","journal-title":"Med Res Rev."},{"issue":"11","key":"10.1016\/j.phrs.2022.106565_bib67","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41568-021-00386-6","article-title":"Targeting the DNA damage response in immuno-oncology: developments and opportunities","volume":"21","author":"Chabanon","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.phrs.2022.106565_bib68","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.phrs.2022.106565_bib69","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Disco"},{"issue":"7898","key":"10.1016\/j.phrs.2022.106565_bib70","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41586-022-04403-y","article-title":"C. Genomics England Research, G.P. Colorectal Cancer Domain Uk, A. Schuh, K. Aden, C. Palles, E. Campo, T. Stankovic, M.S. Taylor, A.P. Jackson, Signatures of TOP1 transcription-associated mutagenesis in cancer and germline","volume":"602","author":"Reijns","year":"2022","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.phrs.2022.106565_bib71","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","article-title":"Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors","volume":"36","author":"Thomas","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106565_bib72","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1038\/s41467-021-23136-6","article-title":"Structural basis for allosteric regulation of Human Topoisomerase IIalpha","volume":"12","author":"Vanden Broeck","year":"2021","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.phrs.2022.106565_bib73","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1039\/C1NP00068C","article-title":"Angucyclines: biosynthesis, mode-of-action, new natural products, and synthesis","volume":"29","author":"Kharel","year":"2012","journal-title":"Nat. Prod. Rep."},{"issue":"Pt 1","key":"10.1016\/j.phrs.2022.106565_bib74","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.semcancer.2018.02.002","article-title":"Cancer molecular markers: a guide to cancer detection and management","volume":"52","author":"Nair","year":"2018","journal-title":"Semin Cancer Biol."},{"issue":"11","key":"10.1016\/j.phrs.2022.106565_bib75","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3390\/genes10110859","article-title":"Cell cycle-dependent control and roles of DNA topoisomerase II","volume":"10","author":"Lee","year":"2019","journal-title":"Genes"},{"issue":"11","key":"10.1016\/j.phrs.2022.106565_bib76","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrm.2016.111","article-title":"Roles of eukaryotic topoisomerases in transcription, replication and genomic stability","volume":"17","author":"Pommier","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"12","key":"10.1016\/j.phrs.2022.106565_bib77","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/bjc.1996.286","article-title":"Differential expression of the topoisomerase II alpha and beta genes in human breast cancers","volume":"73","author":"Sandri","year":"1996","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2022.106565_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2018.101084","article-title":"ROS and the DNA damage response in cancer","volume":"25","author":"Srinivas","year":"2019","journal-title":"Redox Biol."},{"issue":"7713","key":"10.1016\/j.phrs.2022.106565_bib79","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41586-018-0261-5","article-title":"High speed of fork progression induces DNA replication stress and genomic instability","volume":"559","author":"Maya-Mendoza","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.phrs.2022.106565_bib80","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","article-title":"Cell cycle control in cancer","volume":"23","author":"Matthews","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"15","key":"10.1016\/j.phrs.2022.106565_bib81","first-page":"1504","article-title":"Topoisomerase II inhibitors and poisons, and the influence of cell cycle checkpoints","volume":"24","author":"Gabrielli","year":"2017","journal-title":"Curr. Med Chem."},{"issue":"6","key":"10.1016\/j.phrs.2022.106565_bib82","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/0092-8674(87)90518-6","article-title":"DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe","volume":"50","author":"Uemura","year":"1987","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.phrs.2022.106565_bib83","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1073\/pnas.85.4.1086","article-title":"Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle","volume":"85","author":"Heck","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.phrs.2022.106565_bib84","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2443.2002.00521.x","article-title":"ICRF-193, a catalytic inhibitor of DNA topoisomerase II, inhibits re-entry into the cell division cycle from quiescent state in mammalian cells","volume":"7","author":"Hossain","year":"2002","journal-title":"Genes Cells"},{"issue":"10","key":"10.1016\/j.phrs.2022.106565_bib85","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2443.2004.00783.x","article-title":"DNA topoisomerase II is required for the G0-to-S phase transition in Drosophila Schneider cells, but not in yeast","volume":"9","author":"Hossain","year":"2004","journal-title":"Genes Cells"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822005114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822005114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:36:23Z","timestamp":1760913383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822005114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":85,"alternative-id":["S1043661822005114"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106565","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Upgrade of chrysomycin A as a novel topoisomerase II inhibitor to curb KRAS-mutant lung adenocarcinoma progression","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106565","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106565"}}